Clinical Trials Assessing the Optimal Management of Brain Metastases - the State of Play

Clinical Oncology

Volumn 18, Issue 10, 2006, Pages 744-746

  Khanduri, S ^a   Gerrard, G ^a   Barton, R ^b   Mulvenna, P ^c   Lee, S M ^d  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ERLOTINIB;

BRAIN METASTASIS; BRAIN RADIATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MEDICAL SPECIALIST; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOSURGERY; SOLID TUMOR; STEROID THERAPY; UNITED KINGDOM;

BRAIN NEOPLASMS; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY; STEROIDS; TREATMENT OUTCOME;

EID: 33750448297     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.08.009     Document Type: Editorial

References (23)

1. Wen P.Y., Black P.M., and Loeffler J.S. Treatment of metastatic cancer. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer principles and practice of oncology. 6th edn (2001), Lippincott Williams and Wilkins, Philadelphia 2655-2670
2. Gerrard G.E., and Franks K.N. Overview of brain, spine and meningeal metastases. J Neurol Neurosurg Psychiatr 75 (2004) 37-42
3. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. Cancer J Clin 49 (1999) 33-64
4. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 (2004) 2865-2872
5. Priestman T.J., Dunn J., Brada M., et al. Final results of the RCR trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol 8 (1996) 308-315
6. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997) 745-751
7. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
8. Mammon H.J., Yeap B.Y., Jänne P.A., et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23 (2005) 1530-1537
9. Hoskin P.J., and Brada M. Consensus Statement: radiotherapy for brain metastases. Clin Oncol 13 (2001) 91-94
10. Tsao M.N., Sultanem K., Chiu D., et al. Supportive care management of brain metastases: what is known and what we need to know. Clin Oncol 15 (2003) 429-434
11. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single brain metastases to the brain. A randomized trial. JAMA 280 17 (1998) 1485-1489
12. Borgelt B., Gelber R., Kramer S., et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6 (1980) 1-9
13. Kurtz J.M., Gelber G., Brady L.W., et al. The palliation of brain metastases in a favourable patient population: a randomized trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7 (1981) 891-895
14. Horton J., Baxter D.H., Olson K.B., et al. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 3 (1971) 334-336
15. Bezjak A., Adam J., Barton R., et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38 (2002) 487-496
16. Chow E., Davis L., Holden L., et al. Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage 30 (2005) 18-23
17. Shepherd F., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353 (2005) 123-132
18. Cappuzzo F., Calandri C., Bartolini S., et al. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 89 (2003) 246-247
19. Ceresoli G.L., Cappuzzo F., Gregorc V., et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15 (2004) 1042-1047
20. Hotta K., Kiura K., Ueoka H., et al. Effect of gefitinib (Iressa ZD 1839) on brain metastases in patients with advanced non-small cell lung cancer. Lung Cancer 46 2 (2004) 255-261
21. Namba Y., Kijama T., Yokota S., et al. Gefitinib in patients with brain metastases from non-small cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 6 2 (2004) 123-128
22. Chiu C.H., Tsai C.M., Chen Y.M., et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47 1 (2005) 129-138
23. Lai C.S.L., Boshoff C., Falzon M., et al. Complete response to erlotinib therapy in brain metastases from recurrent non-small cell lung cancer. Thorax 61 (2006) 91